{"transactions":[{"id":848764,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-11T20:13:06.000Z","date":"2026-03-09","kind":"grant","planned":false,"acquired":true,"shares":105840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":105840,"derivative":{"exercise_price":7.03,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":105840},"source":{"system":"sec-edgar","filing":"0001610717-26-000092","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071726000092/form4.xml","form_type":"4"}},{"id":1084743,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-18T21:14:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":179800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":179800,"derivative":{"exercise_price":8.68,"expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":179800},"source":{"system":"sec-edgar","filing":"0001610717-25-000290","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000290/form4.xml","form_type":"4"}},{"id":1228997,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-04T21:33:51.000Z","date":"2025-02-28","kind":"grant","planned":false,"acquired":true,"shares":140103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":140103,"derivative":{"exercise_price":16.87,"expiration_date":"2035-02-28","underlying":"Common Stock","underlying_shares":140103},"source":{"system":"sec-edgar","filing":"0001610717-25-000046","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071725000046/form4.xml","form_type":"4"}},{"id":1412780,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-06T20:23:18.000Z","date":"2024-09-04","kind":"grant","planned":false,"acquired":true,"shares":33920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":33920,"derivative":{"exercise_price":11.74,"expiration_date":"2034-09-04","underlying":"Common Stock","underlying_shares":33920},"source":{"system":"sec-edgar","filing":"0001610717-24-000465","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000465/form4.xml","form_type":"4"}},{"id":1603384,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-04T22:41:28.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":965435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":965435,"derivative":{"exercise_price":1.13,"expiration_date":"2024-03-01","underlying":"Common Stock","underlying_shares":965435},"source":{"system":"sec-edgar","filing":"0001610717-24-000121","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000121/form4.xml","form_type":"4"}},{"id":1612473,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":57749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":57749,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":57749},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612472,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":230999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date."}],"balance_after":230999,"derivative":{"exercise_price":0.96,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":230999},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612471,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-28","kind":"grant","planned":false,"acquired":true,"shares":132352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary."}],"balance_after":132352,"derivative":{"exercise_price":0.96,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":132352},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612470,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2025-02-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":80850},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612469,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":323400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":3.06,"exercise_date":"2022-03-04","expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":323400},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1612468,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-28T22:32:12.000Z","date":"2024-02-27","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share."}],"balance_after":0,"derivative":{"exercise_price":16.18,"exercise_date":"2021-01-01","expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001610717-24-000098","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071724000098/form4.xml","form_type":"4"}},{"id":1754334,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2023-10-27T20:14:22.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":305138,"price":0.125,"value":38142.25,"ownership":{"direct":true},"balance_after":305138,"derivative":{"exercise_price":0.7568,"exercise_date":"2023-10-25","expiration_date":"2030-10-25","underlying":"Common Stock","underlying_shares":305138},"source":{"system":"sec-edgar","filing":"0001610717-23-000319","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000319/form4.xml","form_type":"4"}},{"id":1754333,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-10-27T20:14:22.000Z","date":"2023-10-25","kind":"grant","planned":false,"acquired":true,"shares":610277,"price":0.7568,"value":461857.6336,"ownership":{"direct":true},"balance_after":1847575,"source":{"system":"sec-edgar","filing":"0001610717-23-000319","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000319/form4.xml","form_type":"4"}},{"id":1783006,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-12T20:05:19.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":0.84,"expiration_date":"2033-09-08","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610717-23-000273","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000161071723000273/form4.xml","form_type":"4"}},{"id":1947232,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T20:09:57.000Z","date":"2023-03-15","kind":"grant","acquired":true,"shares":242500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":242500,"derivative":{"exercise_price":1.34,"expiration_date":"2033-03-15","underlying":"Common Stock","underlying_shares":242500},"source":{"system":"sec-edgar","filing":"0001567619-23-005251","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761923005251/doc1.xml","form_type":"4"}},{"id":2209237,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-11T20:13:10.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":161700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":161700,"derivative":{"exercise_price":1.41,"expiration_date":"2032-07-07","underlying":"Common Stock","underlying_shares":161700},"source":{"system":"sec-edgar","filing":"0001567619-22-013866","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922013866/doc1.xml","form_type":"4"}},{"id":2408523,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-08T21:09:28.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":80850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date."}],"balance_after":80850,"derivative":{"exercise_price":3.06,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":80850},"source":{"system":"sec-edgar","filing":"0001567619-22-002892","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922002892/doc1.xml","form_type":"4"}},{"id":2408522,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-08T21:09:28.000Z","date":"2022-02-04","kind":"grant","acquired":true,"shares":323400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date."}],"balance_after":323400,"derivative":{"exercise_price":3.06,"expiration_date":"2032-02-04","underlying":"Common Stock","underlying_shares":323400},"source":{"system":"sec-edgar","filing":"0001567619-22-002892","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761922002892/doc1.xml","form_type":"4"}},{"id":2958791,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-04T01:03:08.000Z","date":"2020-12-01","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":450000,"derivative":{"exercise_price":16.18,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001567619-20-020621","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920020621/doc1.xml","form_type":"4"}},{"id":3003065,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1452,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1452},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003064,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":1452,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1452},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003063,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":21695,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21695},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003062,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":3394,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3394},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003061,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":3394,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3394},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003060,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series B-1 Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":50712,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50712},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003059,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13671},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003058,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":13671,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13671},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003057,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":122601,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":122601},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003056,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Preferred Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":41016,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41016},"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003055,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1452,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":18517,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003054,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":1452,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":18517,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003053,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":21695,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":113423,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003052,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":3394,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":17065,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003051,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":3394,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":17065,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003050,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":50712,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":91728,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003049,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":13671,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Zoe Anne Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":13671,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003048,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":13671,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Zachary David Blatt Irrevocable Trust dated 8/24/14."}],"balance_after":13671,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003047,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":122601,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA"}],"balance_after":122601,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}},{"id":3003046,"issuer":{"id":7352,"kind":"organization","name":"Aligos Therapeutics, Inc."},"owners":[{"id":61515,"kind":"person","name":"BLATT LAWRENCE","position":1,"cik":"0001242110","reported_name":"BLATT LAWRENCE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-10-20T20:55:08.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":41016,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Lawrence M. Blatt Living Trust dated 8/27/14."}],"balance_after":41016,"source":{"system":"sec-edgar","filing":"0001567619-20-018001","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1799448/000156761920018001/doc1.xml","form_type":"4"}}]}